Skip to main content
Article thumbnail
Location of Repository

Risk of Fracture with Thiazolidinediones: Disease or Drugs?

By Marloes T. Bazelier, Peter Vestergaard, Arlene M. Gallagher, Tjeerd-Pieter van Staa, Cyrus Cooper, Hubert G. M. Leufkens and Frank de Vries


The use of thiazolidinediones (TZDs) has been associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) has been linked with fracture. We evaluated to what extent the association between TZD use and fracture risk is related to the drug or to the underlying disease. We conducted a population-based cohort study using the Danish National Health Registers (1996–2007), which link pharmacy data to the national hospital registry. Oral antidiabetic users (n = 180,049) were matched 1:3 by year of birth and sex to nonusers. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture. Time-dependent adjustments were made for age, comorbidity, and drug use. We created a proxy indicator for the severity of disease. The first stage was defined as current use of either a biguanide or a sulfonyluerum, the second stage as current use of a biguanide and a sulfonyluerum at the same time, the third stage as patients using TZDs, and the fourth stage as patients using insulin. The risk of osteoporotic fracture was increased 1.3-fold for stages 3 and 4 compared with controls. Risk with current TZD use (stage 3 HR = 1.27, 95 % CI 1.06–1.52) and risk with current use of insulin (stage 4 HR = 1.25, 95 % CI 1.20–1.31) were similar. In the first (HR = 1.15, 95 % CI 1.13–1.18) and second (HR = 1.00, 95 % CI 0.96–1.04) stages risks were lower. Risk of osteoporotic fracture was similar for TZD users and insulin users. When studying fracture risk with TZDs, the underlying T2DM should be taken into account

Topics: Original Research
Publisher: Springer-Verlag
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2009). A cohort study of thiazolidinediones and fractures in older adults with diabetes.
    2. (2008). Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial.
    3. (2004). Bone is a target for the AD compound rosiglitazone.
    4. (1997). Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures.
    5. (1997). Bone mineral density in type II diabetics with macroangiopathy.
    6. (1979). Bone mineral loss in insulintreated diabetes mellitus: studies on pathogenesis.
    7. (2010). Cardiovascular risk and thiazolidinediones—what do meta-analyses really tell us?
    8. (2006). Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways.
    9. (1991). Diabetic bone disease.
    10. (2007). Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a metaanalysis.
    11. (1999). Fellstro ¨m B
    12. (2008). FRAX and the assessment of fracture probability in men and women from the UK.
    13. (1999). Impact of peripheral neuropathy on bone density in patients with type 1 diabetes.
    14. (2002). Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus.
    15. (2005). Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues.
    16. (2009). Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
    17. (2005). Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
    18. (2007). PROactive Investigators
    19. (1997). Regulation of osteoclastic bone resorption by glucose.
    20. (2011). Relationship between obesity and diabetes in a US adult population: findings from the national health and nutrition examination survey,
    21. (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
    22. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
    23. (2007). Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.
    24. (2008). Skeletal consequences of thiazolidinedione therapy.
    25. (2004). Skeletal involvement in patients with diabetes mellitus.
    26. (2007). Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.
    27. (1999). The Danish national hospital register. A valuable source of data for modern health sciences.
    28. (1995). The national patient registry. Evaluation of data quality.
    29. (2007). The peroxisome proliferator-activated receptorgamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
    30. (2009). The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
    31. (2010). Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.
    32. (2004). Thiazolidinediones.
    33. (2008). Use of thiazolidinediones and fracture risk.
    34. (1982). Vitamin D metabolites in diabetic patients: decreased serum concentration of 24,25-dihydroxyvitamin D.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.